DendriticCell and Tumor Cell Cancer Vaccines Market, by Antigen (CD8, CD4, HER2,T-Helper Cell, and Others), by Application (Glioblastoma Cancer, ProstateCancer, Pancreatic Cancer, Colorectal Cancer, Renal Cancer, Lung Cancer, andOthers) by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, andOnline Pharmacies), and by Region (North America, Latin America, Europe, AsiaPacific, Middle East, and Africa) – Size, Share, Outlook, and OpportunityAnalysis, 2019 – 2027
Cancer is an abnormal growth ofcells in the body, also known as malignancy. It has the potential to replicateitself rapidly and invade into other body parts also. There are numerous typesof cancer present. Dendritic cells (part of neuron) plays an important role ininducing anti-tumor activity. Hence, various strategies are being developed totreat cancer with the help of dendritic cell. For generation of dendriticvaccine, dendritic cells are cultured alongside the cancer cells. The vaccine,when induced into body stimulates the immune system to attack cancer cells.
Global Dendritic Cell and TumorCell Vaccines Market Drivers
Increase in research anddevelopment activities related to dendritic cell and tumor cell based vaccinesare expected to accelerate the global dendritic cell and tumor cell vaccinesmarket growth. For instance, in March 2015, Rockefeller University and MemorialSloan Kettering Cancer Center conducted a phase II study of autologousdendritic cell vaccines (DC/PC3). It is being used as an immunotherapy in theprostate cancer. The vaccine was developed by patient’s own cells.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/2753
Furthermore, in April 2016,Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.)S.r.l., began its study on autologous dendritic cells loaded with autologoustumor homogenate in combination with the drug IL-2. It is being used for thetreatment of patients with stage IV colorectal cancer. The purpose of study isto evaluate the consistency of the response of immune cells after completion ofthe treatment. Currently, the study is in its second phase of clinical trials.Hence, such research and development activities of dendritic cell and tumorcell vaccines are expected to impel the global dendritic cell and tumor cellvaccines market growth.
Approvals of vaccines byregulatory bodies are expected to drive the global dendritic cell and tumorcell vaccines market growth. For instance, in June 2018, NorthwestBioTherapeutics received U.S. Food & Drug Administration (FDA) approval forits dendritic cell vaccine, DCVax – L. It is being used for the treatment ofcancer type, glioblastoma. Its clinical study revealed that many patientssurvived for over one and half years after the vaccination. Hence, suchapproved vaccines based on dendritic cell are expected to drive the globaldendritic cell and tumor cell vaccine market growth.
Global Dendritic Cell and TumorCell Vaccines Market Regional Analysis
North America is expected to be adominant region in the global dendritic cell and tumor cell vaccines market,with increasing prevalence of cancer in the region. According to NationalInstitutes of Health (NIH) data, in 2018, around 609,640 people died due tocancer and incidence rate was 439.2 per 100,000 men and women per year. Themost occurring cancer type are breast cancer, lung and bronchus cancer,prostate cancer, colon and rectum cancer, melanoma of the skin, bladder cancer,non-Hodgkin lymphoma, and kidney and renal pelvis cancer. Hence, the higherprevalence of cancer may lead to higher demand for dendritic cell and tumorcell vaccines and thereby, expected to propel the global dendritic cell andtumor cell vaccine market growth.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/dendritic-cell-and-tumor-cell-cancer-vaccines-market-2753
Global Dendritic Cell and TumorCell Vaccines Market Restraints
Withdrawal of dendritic cell andtumor cell vaccines from its clinical trials are expected to hamper the globaldendritic cell and tumor cell vaccines clinical progress. For instance, inMarch 2016, Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori,conducted its clinical trial for dendritic cell vaccine with radiotherapy. Itwas being studied for the treatment of renal cancer. However, it got withdrawnin its second phase of clinical trial (reason unspecified). Hence, this factormay have a negative impact on the global dendritic and tumor cell vaccinemarket growth.
Global Dendritic Cell and TumorCell Vaccines Market Key Players
Some of the major playersoperating in the global dendritic cell and tumor cell vaccines market include,JW CreaGene, Miltenyi Biotec, GlaxoSmithKline plc, NorthWest BioTherapeutics,ImmunoCellular Therapeutics, Ltd., EnoChian Biosciences, Medigene AG, DC Prime,Tella Incorporation, and CiMaas
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/2753
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
